Alpelisib

Drug Overview

The medication known as alpelisib (marketed under the brand name Piqray) is a groundbreaking “targeted therapy” used in the treatment of advanced breast cancer. It belongs to a modern class of precision medicines that do not simply kill all fast-growing cells like chemotherapy; instead, it targets a specific genetic “driver” that allows cancer cells to multiply out of control.

Alpelisib is specifically designed for patients whose cancer has a mutation in the PIK3CA gene. This mutation is found in approximately 40% of patients with HR+/HER2- advanced breast cancer. By blocking the signal produced by this mutation, alpelisib can slow or even stop tumor growth in patients who have already failed other hormonal therapies.

• Generic Name: Alpelisib.
• US Brand Names: Piqray.
• Drug Class: Phosphoinositide 3-Kinase (PI3K) Inhibitor.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: FDA-approved for use in combination with fulvestrant for postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.

What Is It and How Does It Work? (Mechanism of Action)

Alpelisib is a “Smart Drug” that functions as a highly selective kinase inhibitor. To understand how it works at the molecular level, we must look at the signaling highway that cancer cells use to survive.

The PI3K Pathway

In a healthy cell, the PI3K (phosphoinositide 3-kinase) pathway acts as a relay station, sending signals that tell the cell when to grow and when to use energy. In many breast cancers, the PIK3CA gene (which creates the alpha isoform of the PI3K protein) becomes mutated. This mutation keeps the relay station permanently stuck in the “ON” position, leading to uncontrolled cell division and resistance to standard hormonal treatments.

Molecular Level Mechanisms

1. Selective Inhibition: Alpelisib is an alpha-specific PI3K inhibitor. It binds directly to the p110α catalytic subunit of the PI3K enzyme. Unlike older, non-selective inhibitors, alpelisib specifically targets the “alpha” version, which reduces some side effects while maximizing the attack on the mutated cancer signal.
2. Stopping the Signal: Once alpelisib binds to the enzyme, it blocks the phosphorylation of PIP2 to PIP3. This disruption breaks the signaling chain.
3. Inhibition of AKT Activation: Because PIP3 is not produced, the downstream protein AKT cannot be activated. Without AKT signaling, the cancer cell loses its “survival instructions,” causing it to stop growing and eventually die.
4. Overcoming Resistance: Many breast cancers become resistant to endocrine therapy (like aromatase inhibitors). By blocking the PI3K pathway, alpelisib “sensitizes” the cancer cells again, allowing hormonal therapies like fulvestrant to work more effectively.

FDA-Approved Clinical Indications

Alpelisib is prescribed based on the genetic profile of the patient’s tumor. Testing for the PIK3CA mutation in blood or tissue is a requirement before starting the drug.

Oncological Uses:

• Advanced or Metastatic Breast Cancer: Used specifically for Hormone Receptor-positive (HR+), HER2-negative, PIK3CA-mutated breast cancer. It must be used in combination with fulvestrant after the cancer has progressed on or after an endocrine-based regimen.

Non-oncological Uses:

• PROS (PIK3CA-Related Overgrowth Spectrum): Under the brand name Vijoice, alpelisib is FDA-approved for adults and children (2 years and older) who have severe manifestations of PROS, a group of rare genetic disorders caused by the same PIK3CA mutation.

Dosage and Administration Protocols

Alpelisib is a daily oral tablet. Because the drug significantly affects how the body processes sugar, strict adherence to administration with food is required.

Clinical Efficacy and Research Results

The approval of alpelisib was based on the landmark SOLAR-1 clinical trial. Data updated through 2020–2025 continues to support its efficacy.

• Progression-Free Survival (PFS): In the SOLAR-1 trial, patients with the PIK3CA mutation who took alpelisib plus fulvestrant saw their median PFS nearly double—from 5.7 months to 11 months—compared to those taking fulvestrant alone.
• Overall Response Rate: Approximately 26.6% of patients with the mutation saw their tumors shrink significantly when treated with the combination, versus only 12.8% in the group without alpelisib.
• Real-World Data (2024): Recent observational studies show that alpelisib is effective even in patients who have previously been treated with CDK4/6 inhibitors (like Ibrance or Kisqali), which are standard first-line treatments.

Safety Profile and Side Effects

Alpelisib has a very specific safety profile related to its mechanism. Because PI3K is involved in how the body uses insulin, high blood sugar is a primary concern.

Common Side Effects (>10%):

• Hyperglycemia (High Blood Sugar): Occurs in nearly 65% of patients. This is the most significant side effect.
• Rash: Often occurring within the first few weeks of treatment.
• Diarrhea and Nausea: Common digestive upsets.
• Fatigue: General tiredness.
• Decreased Appetite and Weight Loss.

Serious Adverse Events:

• Severe Cutaneous Adverse Reactions (SCAR): Rare but serious skin conditions like Stevens-Johnson Syndrome.
• Pneumonitis: Inflammation of the lungs.
• Severe Hyperglycemia: Can lead to ketoacidosis if not managed.

Warning: Patients with a history of Type 2 Diabetes must be monitored very closely, as alpelisib can cause blood sugar levels to spike dangerously.

Management Strategies:

• Glucose Monitoring: Patients must check their fasting blood glucose levels regularly. Many are prescribed the diabetes drug Metformin preventively.
• Antihistamines: Doctors often recommend taking an antihistamine (like Cetirizine) starting on the same day as alpelisib to prevent or lessen the severity of the rash.

Research Areas

Alpelisib is a key subject in Regenerative Medicine and Stem Cell Research concerning “Cancer Stem Cell Signaling.” Researchers are investigating how PI3K inhibitors can target the “dormant” cancer stem cells that survive initial treatment and later cause a relapse. By combining alpelisib with other targeted agents, scientists hope to create a treatment environment that not only kills the tumor but regenerates the patient’s hormonal balance and prevents the “re-seeding” of the cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• PIK3CA Mutation Test: Required via tissue biopsy or a “liquid biopsy” (blood test).
• HbA1c and Fasting Glucose: To establish a baseline for blood sugar.
• Skin Assessment: To monitor for early signs of rash.

Precautions During Treatment:

• Dietary Management: A low-carbohydrate diet may be recommended to help manage blood sugar levels.
• Lung Health: Report any new or worsening cough or shortness of breath immediately.

“Do’s and Don’ts” List:

• DO take the tablets immediately after a meal; food helps the body absorb the drug correctly.
• DO monitor your blood sugar as directed by your doctor.
• DON’T take alpelisib if you have a history of severe skin reactions to other medications.
• DON’T skip doses or change your dose without consulting your oncologist, even if you develop a rash.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Alpelisib is an FDA-approved prescription medication for specific genetic profiles. Always consult with a qualified oncologist or healthcare professional regarding your diagnosis, treatment options, and the management of potential side effects.